ICD10 code of GM1 Gangliosidosis and ICD9 code

The International Classification of Diseases (ICD) codes for GM1 Gangliosidosis are E75.01 in the ICD-10-CM coding system, while the older ICD-9-CM system categorized the condition under code 330.1. These codes are essential for medical billing, clinical documentation, and accessing specialized care for patients living with this rare lysosomal storage disorder.

What is the clinical significance of GM1 Gangliosidosis?

GM1 Gangliosidosis is a progressive, neurodegenerative lysosomal storage disorder caused by a deficiency of the enzyme beta-galactosidase. This deficiency leads to the toxic accumulation of GM1 ganglioside within the cells, particularly in the central nervous system. Because the disease manifests differently depending on the age of onset—ranging from the severe infantile form (Type I) to the more slowly progressive juvenile (Type II) and adult/chronic forms (Type III)—accurate diagnostic coding is vital for tracking the clinical course of GM1 Gangliosidosis across the global medical community.

How are ICD codes utilized for patients with GM1 Gangliosidosis?

Medical providers use the ICD-10 code E75.01 to ensure that insurance companies and healthcare systems recognize the complexity of GM1 Gangliosidosis. Because it is a rare disease, precise coding helps in securing coverage for specialized multidisciplinary care, which may involve neurology, ophthalmology, and physical therapy. Within the DiseaseMaps community, where 83 individuals have shared their experiences, these codes often serve as a common language for families navigating the healthcare system to explain the specific nature of their diagnosis to new medical providers.

What are the primary diagnostic indicators for GM1 Gangliosidosis?

Diagnosing GM1 Gangliosidosis involves a combination of clinical evaluation and biochemical testing. Clinicians often look for a specific constellation of symptoms that distinguish this disorder from other storage diseases. Key diagnostic features include:

• Enzyme Assay: Measuring significantly reduced beta-galactosidase activity in leukocytes or cultured skin fibroblasts.


• Genetic Testing: Identifying pathogenic variants in the GLB1 gene (located on chromosome 3p22.3).


• Ophthalmological Exam: Presence of a "cherry-red spot" in the macula, observed in approximately 50% of infantile-onset cases.


• Radiological Findings: Skeletal abnormalities known as dysostosis multiplex, which are often detected via X-ray.

Is GM1 Gangliosidosis hereditary?

Yes, GM1 Gangliosidosis is inherited in an autosomal recessive pattern. This means that for a child to be affected, they must inherit two copies of the mutated GLB1 gene—one from each carrier parent. Genetic counseling is strongly recommended for families affected by GM1 Gangliosidosis to understand the 25% recurrence risk for each subsequent pregnancy and to explore reproductive options like preimplantation genetic testing (PGT).

Next steps

• Consult with a metabolic geneticist or a pediatric neurologist to confirm the diagnosis and establish a multidisciplinary care plan.


• Connect with the DiseaseMaps community to share experiences with the 83 other members currently navigating life with GM1 Gangliosidosis.


• Register with the National Organization for Rare Disorders (NORD) or the Cure GM1 Foundation to stay updated on emerging clinical trials and therapeutic research.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: GM1 Gangliosidosis (ORPHA:357)


• NIH Genetic and Rare Diseases Information Center (GARD): GM1 Gangliosidosis


• OMIM (Online Mendelian Inheritance in Man): Gangliosidosis, GM1 (Entry #230500)


• Cure GM1 Foundation: Patient Resources and Research Updates